• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Anti-Aging
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

FDA Approves New Dose for Dupilumab Pre-filled Pen

Article

The FDA has approved a single-dose pre-filled pen for dupilumab (Dupixent, Sanofi and Regeneron) for at-home administration.

The FDA has approved a 200 mg single-dose pre-filled pen for dupilumab (Dupixent, Sanofi and Regeneron) for at-home administration in patients 12 years and older across certain indications.

The approved indications include atopic dermatitis and asthma.

The pre-filled pen features a hidden needle and single-press auto-injection, as well as visual and audio feedback to aid in administration. Prior to at-home administration, use of the pre-filled pen requires training by a health care professional.

Recently, the 300 mg dose pre-filled pen was approved by the FDA and is now available.

With the approval of the 200 mg pen, both doses of pre-filled pens have now been approved in the U.S. and European Union.

The new 200 mg pre-filled pen will be available in the U.S. in August 2021.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.